ArticleJournal of ovarian research2026
β-sitosterol improves the pathological progression of PCOS by targeting ESR1 to inhibit autophagy activity.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a prevalent hormonal disorder among women, mainly marked by elevated levels of androgens, irregular ovulation, and the presence of multiple cysts in the ovaries. Eucommia, as a common traditional Chinese medicine for treating PCOS in clinical practice, has β-sitosterol as its main active ingredient. Currently, the mechanism by which Eucommia ulmoides alleviates the pathological progression of PCOS has not been fully explored. PURPOSE: This study aims to explore the mechanism of β-sitosterol in treating the pathological changes of PCOS.
methodsEmploy ultra-high performance liquid chromatography-mass spectrometry to identify the primary active compounds of Eucommia ulmoides, and investigate its possible targets and mechanisms for addressing PCOS using network pharmacology. Molecular docking and molecular dynamics simulations are used to verify the potential interaction and binding of compounds with target proteins. The molecular biology experiments exploring the therapeutic mechanisms were conducted using a PCOS model constructed with rats and KGN cells.
resultsBoth network pharmacology and ultra-high performance liquid chromatography-mass spectrometry results indicate that β-sitosterol is the main active component of Eucommia ulmoides. Furthermore, network pharmacology findings suggest that the potential targets of β-sitosterol for treating PCOS are primarily located within the steroid metabolism pathway. Notably, molecular docking and molecular dynamics simulations reveal that β-sitosterol interacts closely with ESRα and AKT. Both in vivo and in vitro studies have shown that β-sitosterol can prevent the apoptosis of granulosa cells and excessive autophagy activation in PCOS. Furthermore, β-sitosterol exerts an ovarian protective effect by inhibiting autophagy and the apoptosis of granulosa cells through its targeted action on ESRα and AKT.
conclusionsOur research found that β-sitosterol downregulates autophagy activity through the ESR1/AKT/mTOR signaling pathway, thereby inhibiting the apoptosis of granulosa cells and alleviating the pathological progression of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.